Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-Release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-Release Tablets.

Trial Profile

Food Effects on the Relative Bioavailability of a Risedronate 20 mg Delayed-Release [DR] Tablet and to Compare the 20 mg DR Tablet to 35 mg DR and 35 mg Immediate-Release Tablets.

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Oct 2011

At a glance

  • Drugs Risedronic acid (Primary)
  • Indications Male osteoporosis; Postmenopausal osteoporosis
  • Focus Pharmacokinetics
  • Sponsors Procter & Gamble
  • Most Recent Events

    • 24 Mar 2010 Actual patient number (94) added, Warner Chilcott added as trial sponsor and affiliate as reported by ClinicalTrials.gov.
    • 15 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Aug 2008 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top